Continuum Advisory’s VanEck Biotech ETF BBH Stock Holding History

Continuum Advisory’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,262	Closed	-$239K	–	455
2025 Q4	$239K	Buy	+1,262	New	+$233K	0.02%	407
2025 Q2	–	Sell	-1,304	Closed	-$205K	–	512
2025 Q1	$205K	Buy	1,304 +270	+26%	+$43.8K	0.03%	388
2024 Q4	$162K	Hold	1,034	–	–	0.02%	428
2024 Q3	$171K	Buy	1,034 +50	+5%	+$8.87K	0.02%	424
2024 Q2	$166K	Hold	984	–	–	0.02%	397
2024 Q1	$162K	Buy	+984	New	+$163K	0.02%	403
2021 Q4	–	Sell	-1,039	Closed	-$210K	–	304
2021 Q3	$210K	Buy	+1,039	New	+$218K	0.06%	274

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

Continuum Advisory's BBH Position: Q1 2026 in Review

Continuum Advisory sold out of VanEck Biotech ETF (BBH) in Q1 2026, closing a stake of 1,262 shares — an estimated $239K sold.

Continuum Advisory first reported a position in BBH in Q3 2021 and held it in 7 quarters. The position peaked at $239K in Q4 2025. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

Continuum Advisory reported no remaining VanEck Biotech ETF position as of Q1 2026 after selling out during the quarter.
Continuum Advisory sold 1,262 VanEck Biotech ETF shares in Q1 2026, an estimated $239K.
Continuum Advisory first reported a position in VanEck Biotech ETF in Q3 2021 and held it in 7 quarters.
Continuum Advisory's VanEck Biotech ETF position peaked at $239K in Q4 2025.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Continuum Advisory's 13F filing for Q1 2026, filed 22 Apr 2026.